Fourth Annual Novel Antibody Constructs and Alternative Scaffolds
Part One: Creative Engineering, Delivery Technologies and Targeting
Day 1 | Day 2
Part Two | Download Brochure
Tuesday, 6 November
7:30 Registration and Morning Coffee
8:30 Chairperson's Opening Remarks
Dana Ault-Riché, Ph.D., CEO, Reflexion Pharmaceuticals, Inc.
8:35 Engineering Bi-Specific Fynomer-Antibody Fusions for Therapeutic Applications
Julian Bertschinger, Ph.D., CEO, Covagen AG - Biography
Fynomers are small binding proteins derived from the human Fyn SH3 domain. Here, we describe the engineering and characterization of bi-specific Fynomer-antibody fusions targeting two different epitopes on HER2. These Fynomer-antibody fusions prevent effectively proliferation of HER2 positive tumor cells in vitro and in vivo. Engineered Fynomer-antibody fusion proteins have optimal physico-chemical and in vivo half-life properties, making them attractive as drug candidates to be brought into pre-clinical and clinical development.
9:05 High-Throughput Generation of scFv-Fc Antibodies to Novel, Modified and Difficult Targets
Stefan Dübel, Ph.D., Professor, Biotechnology, Technical University of Braunschweig - Biography
Today, the control of the biochemical conditions during a recombinant antibody selection process makes possible the production of human antibodies specific for single post-translational modifications or to antigens in complex membrane preparations. With the technology for the generation of human targeting domains being matured now, it is evident that identification of disease related antigens becomes the limiting factor. Our high-throughput pipeline for the generation of scFv-Fc antibodies can provide lead substances right from the target discovery process.
9:35 A Novel Ligation Technology for Site-Specific Engineering and Labeling of Proteins
Graham Cotton, Ph.D., Senior R&D Group Leader, Almac Group - Biography
Increasingly, protein engineering and labeling technologies are being used to develop biotherapeutics with improved performance and to enable new therapeutic approaches to be realized using protein-based drugs. To this end, we have developed a novel protein ligation methodology for the site-specific C-terminal modification of proteins. This high yielding, highly selective technology provides a facile approach for the C-terminal PEGylation of proteins, and has broad applicability for the labeling and engineering of proteins including the development of bi-specific protein therapeutics and molecular imaging agents.
10:05 Pre-Clinical Advances with PASylated Bi-Specific Combinations of Peptides, Antibody Fragments, and Anticalins
Arne Skerra, Ph.D., CEO, XL-protein GmbH - Biography
PASylation, the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and Ser, allows the facile functional coupling of two different bioactive proteins or peptides. PASylation provides a solvated random chain with large hydrodynamic volume, thus slowing down kidney filtration by a factor 10 to 100 and paving the way to bi-specific drugs with extended plasma half-life. Compared with PEG, PASylation offers several advantages, in particular biodegradability and one-step biotechnological production.
10:35 Coffee Break in the Exhibit Hall with Poster Viewing
11:15 Exploiting the Biophysical Properties of Centyrins: New Therapeutic Targets, Novel Routes of Administration and Valuable Tools for Drug Discovery
Robert Hayes, Ph.D., Vice President and Venture Leader, Centyrex Venture, Janssen Research & Development - Biography
Alternative scaffolds represent an emerging of protein therapeutics. We have designed novel consensus FN3 domains, called Centyrins, which have excellent biophysical properties. We are exploiting the robustness of this platform to develop a series of molecules aimed at broadening the therapeutic applications of biologics to areas such as bi-specific drugs, intracellular inhibitors, and alternative routes of drug delivery. By applying automation and high-throughput selections, these molecules are also being used as tools for large and small molecule drug discovery.
11:45 Topical/Local Administration of Single Chain Fv Antibody Fragments in Clinical Settings
Titus Kretzschmar, Ph.D., CSO, Delenex Therapeutics AG - Biography
12:15 Sponsored Presentation
(Opportunity available, please contact Carol Dinerstein, Dinerstein@healthtech.com)
12:30 Luncheon Presentations or Lunch on Your Own
(Opportunities available, please contact Carol Dinerstein, Dinerstein@healthtech.com)
14:15 Chairperson's Remarks
Stefan Dübel, Ph.D., Professor, Biotechnology, Technical University of Braunschweig
14:20 Engineering and Development of Tri-Specific Molecules with Long Plasma Half-Life for Subcutaneous Administration
Joachim Feldwisch, Ph.D., Director, Preclinical Discovery, Affibody AB
A practical obstacle for self-administered subcutaneous injections is the maximal volume that can be injected subcutaneously, as this limits the amount of drug that can be administered. Here we will present our technology for engineering of a minimal multispecific biological substance to increase the dose after subcutaneous administration, animal results of the use of our broad-species cross-reactivity half-life extension technology, and our work to address the challenge of finding a configuration that binds all three targets optimally.
14:50 Treating Ocular and Pulmonary Diseases with Therapeutic Mirror Proteins
Dana Ault-Riché, Ph.D., CEO, Reflexion Pharmaceuticals, Inc. - Biography
Mirror proteins are chemically produced entirely out of D-amino acids, making them highly stable, metabolically inert and non-immunogenic, while retaining antibody-like affinity and specificity. Reflexion uses this unique combination of properties to enable new ocular and pulmonary dosing strategies. Reflexion is developing a VEGF-A antagonist to treat wet age-related macular degeneration and diabetic macular edema by drops and an inhaled VEGF-D antagonist to treat a rare disease called lymphangioleimyomatosis (LAM), which primarily afflicts young women and currently has no effective treatment.
15:20 Transfer'rin Antibodies into the Brain
Mark S. Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc. - Biography
Antibodies have a vast therapeutic potential for treatment of CNS diseases, but their passage into the brain is restricted by the blood-brain barrier (BBB). Our most recent efforts to harness receptor-mediated transcytosis pathways of brain endothelial cells in order to deliver a therapeutically relevant dose of antibody across the BBB will be discussed.
15:50 Refreshment Break in the Exhibit Hall with Poster Viewing
16:30 Sponsored Presentation (Opportunities available, please contact Carol Dinerstein, Dinerstein@healthtech.com)
17:00 Problem Solving Roundtable Discussions
Table 1: The Quest for New and Better Targets for Bispecifics
Moderator: Rebecca Ashfield, Ph.D., Portfolio and Collaborations Manager, Immunocore Ltd.
Table 2: Engineering of Bispecific Antibodies
Moderators: Julian Bertschinger, Ph.D., CEO, Covagen AG and Gregory Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center
Table 3: Small Immunoglobulin Fragments vs. Alternative Scaffolds
Moderator: Christian Heinis, Ph.D., Laboratory of Therapeutic Proteins and Peptides, Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL)
Table 4: Issues to do with Formulation and Delivery
Moderator: Dana Ault-Riché, Ph.D., CEO, Reflexion Pharmaceuticals, Inc.
Table 5: Challenges of Targeting Membrane Spanning Proteins
Moderator: Jonathan Belk, Ph.D., Senior Scientist II, Technology and Platform Development, Adimab, LLC.
Table 6: How to Get What You Want From Antibody Phage Display
Moderators: Stefan Dübel, Ph.D., Professor, Biotechnology, Technical University of Braunschweig and John McCafferty, Ph.D., Research Director, Biochemistry, University of Cambridge
18:00-19:00 Welcome Reception in the Exhibit Hall with Poster Viewing
Day 1 | Day 2
Part Two | Download Brochure